Skip to main content
Journal cover image

Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAg-) on anti-TNF therapy have a low rate of reactivation.

Publication ,  Journal Article
Clarke, WT; Amin, SS; Papamichael, K; Feuerstein, JD; Cheifetz, AS
Published in: Clin Immunol
June 2018

Anti-TNF agents are widely used to treat immune-mediated disorders. Reactivation of Hepatitis B virus (HBV) is associated with immunosuppressive agents and biologics such as anti-TNF. There are limited data and differing guidelines for patients with negative hepatitis B surface antigen (HBsAg-) but positive antibody to hepatitis B core antigen (anti-HBc+) on anti-TNF with regards to outcomes and need for anti-viral prophylaxis. We examined the prevalence of HBV reactivation in a single-center retrospective cohort study of 120 HBsAg-, anti-HBc+ patients on anti-TNF, totaling 346.6 patient years. One patient (0.8%) who had a detectable VL (<20 IU) prior to starting anti-TNF had reactivation of HBV with sero-conversion to positive HBsAg. Three patients (2.5%) had undetectable HBV VL prior to anti-TNF and developed detectable VL while on anti-TNF. In conclusion, there was a low rate of HBV reactivation or development of detectable HBV DNA in HBsAg-, anti-HBc+ patients on anti-TNF.

Duke Scholars

Published In

Clin Immunol

DOI

EISSN

1521-7035

Publication Date

June 2018

Volume

191

Start / End Page

59 / 62

Location

United States

Related Subject Headings

  • Virus Activation
  • Tumor Necrosis Factor-alpha
  • Middle Aged
  • Male
  • Immunology
  • Humans
  • Hepatitis B virus
  • Hepatitis B Surface Antigens
  • Hepatitis B Core Antigens
  • Hepatitis B Antibodies
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Clarke, W. T., Amin, S. S., Papamichael, K., Feuerstein, J. D., & Cheifetz, A. S. (2018). Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAg-) on anti-TNF therapy have a low rate of reactivation. Clin Immunol, 191, 59–62. https://doi.org/10.1016/j.clim.2018.03.013
Clarke, William T., Shreya S. Amin, Konstantinos Papamichael, Joseph D. Feuerstein, and Adam S. Cheifetz. “Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAg-) on anti-TNF therapy have a low rate of reactivation.Clin Immunol 191 (June 2018): 59–62. https://doi.org/10.1016/j.clim.2018.03.013.
Clarke, William T., et al. “Patients with core antibody positive and surface antigen negative Hepatitis B (anti-HBc+, HBsAg-) on anti-TNF therapy have a low rate of reactivation.Clin Immunol, vol. 191, June 2018, pp. 59–62. Pubmed, doi:10.1016/j.clim.2018.03.013.
Journal cover image

Published In

Clin Immunol

DOI

EISSN

1521-7035

Publication Date

June 2018

Volume

191

Start / End Page

59 / 62

Location

United States

Related Subject Headings

  • Virus Activation
  • Tumor Necrosis Factor-alpha
  • Middle Aged
  • Male
  • Immunology
  • Humans
  • Hepatitis B virus
  • Hepatitis B Surface Antigens
  • Hepatitis B Core Antigens
  • Hepatitis B Antibodies